Skip to main content
SpringerLink
Log in

Amivantamab/erlotinib/patritumab-deruxtecan

Acquired drug resistance: 4 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Basse C, et al. Gain of Aggressive Histological and Molecular Patterns after Acquired Resistance to Novel Anti-EGFR Therapies in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences 24: No. 4, 14 Feb 2023. Available from: URL: http://doi.org/10.3390/ijms24043802

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Amivantamab/erlotinib/patritumab-deruxtecan. Reactions Weekly 1949, 46 (2023). https://doi.org/10.1007/s40278-023-36026-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-36026-6

Search

Navigation